Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation

JCO Precis Oncol. 2023 Jun:7:e2200633. doi: 10.1200/PO.22.00633.

Michael L Cheng^{1

2}, Yeying Huang³, Nhi Luong³, Jaclyn LoPiccolo^{1

2}, Mizuki Nishino^{4

5}, Lynette M Sholl³, Lucian R Chirieac³, Alison D Santucci^{1

6}, Michael S Rabin^{1

2}, Pasi A Jänne^{1

2}, Shodeinde Coker⁷, Jennifer R Diamond⁸, John Hilton⁹, Geoffrey I Shapiro², Christopher A French³

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
² Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
³ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
⁴ Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
⁵ Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
⁶ Boston Medical Center, Boston, MA.
⁷ Bristol Myers Squibb, Lawrenceville, NJ.
⁸ University of Colorado Cancer Center, Aurora, CO.
⁹ Division of Medical Oncology, Ottawa Hospital, Ottawa, ON.

No abstract available

Publication types